RxDoctor Payments Data

Whitney Lovett

Family · Forsyth, GANPI 1922637354

Payments from drug & device makers

$4,990in general payments, 2019–2025

Across 283 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$716
  • Novo Nordisk$520
  • Astellas Pharma US Inc$516
  • AstraZeneca$465
  • Otsuka America Pharmaceutical, Inc.$382
  • Takeda Pharmaceuticals U.S.A., Inc.$326
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$4,81096%
  • Education$1804%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,990 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$23,212
Medicare patients
119
Services billed
3,703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide54$63,150
OzempicSemaglutide47$49,310
JanuviaSitagliptin Phosphate33$34,756
FarxigaDapagliflozin Propanediol28$28,855
EliquisApixaban22$26,141
TrulicityDulaglutide12$13,629
MyrbetriqMirabegron12$12,896
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$11,093
Janumet XrSitagliptin Phos/Metformin Hcl11$10,655
LinzessLinaclotide16$9,486
EdarbiAzilsartan Medoxomil17$7,428
Atorvastatin Calcium118$1,590
Albuterol Sulfate HfaAlbuterol Sulfate62$1,548
Omeprazole97$1,405
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,280

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$716$76,77966 claims
Novo NordiskOzempic$520$49,31047 claims
MerckJanuvia, Janumet Xr$45$45,41144 claims
AstraZenecaFarxiga, Breztri Aerosphere$465$39,94844 claims
PfizerEliquis$144$26,14122 claims
Astellas Pharma US IncMyrbetriq$516$12,89612 claims
AbbVieLinzess$253$9,48616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Forsyth

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →